Poolbeg Pharma PLC (POLB) - Total Assets
Based on the latest financial reports, Poolbeg Pharma PLC (POLB) holds total assets worth GBX9.94 Million GBX (≈ $1.21K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Poolbeg Pharma PLC - Total Assets Trend (2021–2025)
This chart illustrates how Poolbeg Pharma PLC's total assets have evolved over time, based on quarterly financial data. Also see Poolbeg Pharma PLC (POLB) market capitalisation for the company's overall valuation and market capitalisation.
Poolbeg Pharma PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Poolbeg Pharma PLC's total assets of GBX9.94 Million consist of 83.2% current assets and 16.8% non-current assets. Review Poolbeg Pharma PLC (POLB) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 77.6% |
| Accounts Receivable | GBX364.00K | 3.7% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX1.67 Million | 16.8% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Poolbeg Pharma PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See POLB share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Poolbeg Pharma PLC's current assets represent 83.2% of total assets in 2025, a decrease from 93.2% in 2021.
- Cash Position: Cash and equivalents constituted 77.6% of total assets in 2025, down from 91.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 6.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 16.8% of total assets.
Poolbeg Pharma PLC Competitors by Total Assets
Key competitors of Poolbeg Pharma PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Poolbeg Pharma PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.17 | 8.79 | 175.07 |
| Quick Ratio | 6.17 | 8.79 | 175.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX6.93 Million | GBX7.59 Million | GBX23.10 Million |
Poolbeg Pharma PLC - Advanced Valuation Insights
This section examines the relationship between Poolbeg Pharma PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.37 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | GBX9.94 Million |
| Market Capitalization | $808.13K USD |
Valuation Analysis
Below Book Valuation: The market values Poolbeg Pharma PLC's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Poolbeg Pharma PLC's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Poolbeg Pharma PLC (2021–2025)
The table below shows the annual total assets of Poolbeg Pharma PLC from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX9.94 Million ≈ $1.21K |
-2.98% |
| 2024-12-31 | GBX10.25 Million ≈ $1.25K |
-33.58% |
| 2023-12-31 | GBX15.43 Million ≈ $1.88K |
-20.02% |
| 2022-12-31 | GBX19.29 Million ≈ $2.35K |
-16.20% |
| 2021-12-31 | GBX23.02 Million ≈ $2.80K |
-- |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more